Analyst picks & changes Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 1/23 cls Arrowhead Research Corp. (NASDAQ:ARWR) Deutsche Bank Alethia Young Downgrade Hold (from buy) -6% $6.43 Young also lowered her...

Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 4/25 cls BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) Brinson Patrick Christopher James New Market outperform -4% $8.01 James initiated coverage with a $15 target. He expects...

Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 4/17 cls Akebia Therapeutics Inc. (NASDAQ:AKBA) UBS Matthew Roden New Buy 55% $26.09 Roden initiated coverage with a $28 target on the belief that...

Microfluidics company Fluidigm completed its acquisition of DVS Sciences, which develops and markets single-cell protein analysis systems, for about $207.5 million in a cash and stock deal (see BioCentury, Feb. 3). Fluidigm Corp. (NASDAQ:FLDM), South...

Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 2/7 cls Fluidigm Corp. (NASDAQ:FLDM) Cowen Doug Schenkel Downgrade Market perform (from outperform) -4% $43.11 Schenkel raised his target to $45 from $42, saying...

Microfluidics company Fluidigm is acquiring DVS Sciences for about $207.5 million in a cash and stock deal. DVS develops and markets single-cell protein analysis systems, including its CyTOF2 mass cytometer. Fluidigm said DVS will complement...

A quick turnaround from first financing to takeout netted investors in DVS Sciences Inc. an impressive return in a short time. On Jan. 29, Fluidigm Corp. (NASDAQ:FLDM) announced plans to acquire fellow microfluidics company DVS...

Microfluidics company Fluidigm Corp. (NASDAQ:FLDM) is acquiring DVS Sciences Inc. (Sunnyvale, Calif.) for about $207.5 million in a cash and stock deal. DVS develops and markets single-cell protein analysis systems, including its CyTOF2 mass cytometer....

Approach Summary Licensing status Publication and contact information Drug platforms High throughput flow cytometry for small molecule screening High throughput, multiplexed flow cytometry could provide a way to rapidly screen small molecules in immune cells....

Pfizer Inc. believes new partner Nodality Inc. 's Single Cell Network Profiling technology will provide early insight into a compound's clinical profile, which could help reduce attrition rates, accelerate development and improve patient selection. The...